Wei et al47 studied combination apatinib and camrelizumab, a VEGFR TKI and PD-1 inhibitor, respectively, under investigation in China for a variety of malignancies, as second-line therapy in 21 patients with unresectable or metastatic ACC. This evidence concerns the gene PDCD1 and adrenal cortex carcinoma.